#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1760	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2139	153.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1731	1731	T	131	T	78	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1760	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2139	153.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1465	1465	C	221	C	132	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	3308	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3477	173.2	0	.	n	.	0	T695C	SNP	695	695	T	987	987	C	221	C	134	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	3308	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3477	173.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1629	1629	A	194	A	117	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	3308	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3477	173.2	0	.	n	.	0	A1638G	SNP	1638	1638	A	1930	1930	G	138	G	85	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	3308	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3477	173.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2263	2263	C	185	C	110	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	3308	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3477	173.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2337	2337	A	190	A	113	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	3308	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3477	173.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2889	2889	C	201	C,A	121,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	3308	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3477	173.2	0	HET	.	.	.	C2525T	.	2525	2525	C	2817	2817	C	179	C,T	85,32	.	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	19	82	folP	855	849	100.0	folP.l15.c4.ctg.1	957	14.0	1	SNP	p	R229S	1	.	.	685	687	AGC	793	795	AGC	15;17;16	A;G;C	8;9;9	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	306	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	2771	19.8	1	SNP	p	S91F	1	.	.	271	273	TTC	223	225	TTC	20;20;20	T;T;C	11;12;11	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	306	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	2771	19.8	1	SNP	p	D95G	1	.	.	283	285	GGC	235	237	GGC	22;22;22	G;G;C	12;13;13	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	306	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	2771	19.8	1	SNP	p	G95N	0	.	.	283	285	GGC	235	237	GGC	22;22;22	G;G;C	12;13;13	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	92	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1261	14.2	1	SNP	p	G45D	0	.	.	133	135	GGC	332	334	GGC	33;33;33	G;G;C	18;17;19	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	68	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	573	20.8	0	.	n	.	0	A197.	DEL	197	197	A	320	320	A	33	A	19	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	16	300	parC	2304	2104	100.0	parC.l15.c30.ctg.1	2250	23.5	1	SNP	p	D86N	0	.	.	256	258	GAC	402	404	GAC	25;25;25	G;A;C	16;16;18	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	16	300	parC	2304	2104	100.0	parC.l15.c30.ctg.1	2250	23.5	1	SNP	p	R87W	0	.	.	259	261	CGT	405	407	CGT	25;25;27	C;G;T	18;15;16	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	16	300	parC	2304	2104	100.0	parC.l15.c30.ctg.1	2250	23.5	1	SNP	p	R87I	0	.	.	259	261	CGT	405	407	CGT	25;25;27	C;G;T	18;15;16	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	16	300	parC	2304	2104	100.0	parC.l15.c30.ctg.1	2250	23.5	1	SNP	p	S87R	1	.	.	259	261	CGT	405	407	CGT	25;25;27	C;G;T	18;15;16	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	16	300	parC	2304	2104	100.0	parC.l15.c30.ctg.1	2250	23.5	1	SNP	p	S88P	0	.	.	262	264	TCC	408	410	TCC	27;27;28	T;C;C	17;18;18	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	232	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2649	16.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1595	1597	GGC	15;15;15	G;G;C	9;9;8	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	Y201H	NONSYN	601	603	TAT	731	733	CAT	18;18;18	C;A;T	14;14;14	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	G202A	NONSYN	604	606	GGC	734	736	GCT	22;23;23	G;C;T	16;16;17	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	E203G	NONSYN	607	609	GAA	737	739	GGA	23;23;23	G;G;A	17;17;17	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	D204E	NONSYN	610	612	GAC	740	742	GAA	23;23;23	G;A;A	17;17;17	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	Q214E	NONSYN	640	642	CAG	770	772	GAA	25;25;25	G;A;A	19;18;17	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	P542H	NONSYN	1624	1626	CCC	1754	1756	CAC	13;13;13	C;A;C	9;7;7	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	1	SNP	p	G543S	1	G543S	NONSYN	1627	1629	GGC	1757	1759	AGC	13;15;15	A;G;C	7;7;9	penA.56.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	G548V	NONSYN	1642	1644	GGA	1772	1774	GTA	14;14;14	G;T;A	10;6;7	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	G550A	NONSYN	1648	1650	GGG	1778	1780	GCA	14;14;14	G;C;A	6;6;7	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	G552P	NONSYN	1654	1656	GGG	1784	1786	CCG	13;13;13	C;C;G	6;5;4	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	P554F	NONSYN	1660	1662	CCC	1790	1792	TTC	12;12;12	T;T;C	6;5;7	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	0	.	p	.	0	G559fs	FSHIFT	1675	1675	G	1805	1805	G	12	G	7	.	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1061	1063	GCA	31;31;31	G;C;A	20;19;20	penA.56.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1064	1066	ATC	31;31;31	A;T;C	19;19;18	penA.56.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1076	1078	GTG	34;34;34	G;T,G;G	20;21,1;21	penA.56.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1076	1078	GTG	34;34;34	G;T,G;G	20;21,1;21	penA.56.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1580	1582	ACC	18;18;17	A;C;C	13;11;12	penA.56.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	264	penA	1719	1691	97.87	penA.l15.c4.ctg.1	1822	25.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1766	1768	GGC	15;15;14	G;G;C	10;8;7	penA.56.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	486	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2788	30.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1451	1453	CCG	18;18;18	C;C;G	10;12;12	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	142	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1771	14.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	717	717	C	19	C	11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	H217N	NONSYN	649	651	CAT	263	265	AAT	3;3;3	A;A;T	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	D218N	NONSYN	652	654	GAT	266	268	AAT	3;3;3	A;A;T	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	V226A	NONSYN	676	678	GTA	290	292	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	.	MULTIPLE	700	702	ACT	313	315	GTA	1;1;1	G;T;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	S236N	NONSYN	706	708	AGC	319	321	AAC	1;1;1	A;A;C	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	.	MULTIPLE	709	711	AAC	323	328	TGGCAT	1;1;1;1;1;1	T;G;G;C;A;T	1;1;1;1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	D238A	NONSYN	712	714	GAT	329	331	GCT	1;1;1	G;C;T	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	389	391	TTA	1;1;1	T;T;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	434	436	CAT	3;3;3	C;A;T	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	D274G	NONSYN	820	822	GAT	437	439	GGT	3;3;3	G;G;T	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	16	porB1a	984	287	90.72	porB1a.l15.c4.ctg.1	527	2.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	446	448	TAC	3;3;3	T;A;C	2;2;2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	246	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1710	26.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	476	478	GAA	28;25;25	G;A;A	17;14;15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	246	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1710	26.3	1	SNP	p	D121N	1	D121N	NONSYN	361	363	GAC	725	727	AAC	31;31;32	A;A;C	20;20;20	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	246	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1710	26.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	764	766	GAT	28;29;29	G;A;T	16;18;17	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	246	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1710	26.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	887	889	TCA	43;43;43	T;C;A	25;26;25	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	246	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1710	26.3	0	.	p	.	0	A218I	NONSYN	652	654	GCC	1016	1018	ATC	48;48;47	A;T;C	27;27;26	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	246	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1710	26.3	0	.	p	.	0	R258H	NONSYN	772	774	CGT	1136	1138	CAT	40;38;38	C;A;T	27;24;25	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	246	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1710	26.3	0	.	p	.	0	S295G	NONSYN	883	885	AGT	1247	1249	GGT	44;44;41	G;G;T	27;26;25	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	246	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1710	26.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1346	1348	GCA	34;34;34	G;C;A	21;22;22	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	246	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1710	26.3	1	SNP	p	G120K	1	.	.	358	360	AAG	722	724	AAG	31;31;31	A;A;G	19;20;18	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	898	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4879	33.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	62	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	702	16.9	1	SNP	p	V57M	1	.	.	169	171	ATG	429	431	ATG	13;13;13	A;T;G	9;8;8	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
